REVIEW article

Front. Microbiol., 05 July 2022

Sec. Infectious Agents and Disease

Volume 13 - 2022 | https://doi.org/10.3389/fmicb.2022.926240

Direct Metagenomic Diagnosis of Community-Acquired Meningitis: State of the Art

  • 1. IHU Méditerranée Infection, Marseille, France

  • 2. Aix-Marseille Université, IRD, MEPHI, IHU Méditerranée Infection, Marseille, France

  • 3. VBIC, INSERM U1047, Université de Montpellier, Service de Microbiologie et Hygiène Hospitalière, CHU Nîmes, Nîmes, France

  • 4. Laboratoire de Microbiologie, Assistance Publique-Hôpitaux de Marseille, IHU Méditerranée Infection, Marseille, France

Abstract

Current routine diagnosis of community-acquired meningitis (CAM) by multiplex real-time polymerase chain reaction (RT-PCR) is limited in the number of tested pathogens and their full characterisation, requiring additional in vitro investigations to disclose genotype and antimicrobial susceptibility. We reviewed 51 studies published through December 2021 reporting metagenomic next generation sequencing (mNGS) directly applied to the cerebrospinal fluid (CSF). This approach, potentially circumventing the above-mentioned limitations, indicated 1,248 investigated patients, and 617 patients dually investigated by routine diagnosis and mNGS, in whom 116 microbes were detected, including 50 by mNGS only, nine by routine methods only, and 57 by both routine methods and mNGS. Of 217 discordant CSF findings, 103 CSF samples were documented by mNGS only, 87 CSF samples by routine methods only, and 27 CSF samples in which the pathogen identified by mNGS was different than that found using routine methods. Overall, mNGS allowed for diagnosis and genomic surveillance of CAM causative pathogens in real-time, with a cost which is competitive with current routine multiplex RT-PCR. mNGS could be implemented at point-of-care (POC) laboratories as a part of routine investigations to improve the diagnosis and molecular epidemiology of CAM, particularly in the event of failure of routine assays.

Introduction

Community-acquired meningitis (CAM), a life-threatening condition with 40% mortality (), warrants a rapid diagnosis, possibly within 2 h at a point-of-care (POC) laboratory, providing identification of the causative pathogen among a repertoire of fewer than 20 pathogens (; ; ; ), those most frequently encountered in the general population of patients, and supporting the initial medical decisions for hospitalisation and antibiotic treatment (; ; ). Such a POC diagnosis, which is routinely made using nested or semi-nested polymerase chain reactions (PCRs), is prone to cross-contamination resulting in false-positive diagnoses (; ). Current POC diagnosis also relies on the detection of a limited number of pathogens, and may thus miss microorganisms acting as life-threatening pathogens in selected populations, such as Cryptococcus in HIV-infected patients, in whom Cryptococcus most frequently causes fungal meningitis, with 223,000 new cases each year and 81% mortality (; ) and amoebas, such as Acanthamoeba (; ). The precise characterisation of such detected pathogens, including genotyping and anti-infectious susceptibility profiling, are pieces of medical information which are relevant for the immediate medical management of patients and contacts, and source tracing.

Metagenomic next generation sequencing (mNGS) directly applied to cerebrospinal fluid (CSF) emerged less than 10 years ago, in the specific context of healthcare-associated meningitis (), as an alternative to the laboratory diagnosis of CAM, potentially surpassing above-mentioned limitations of the current multiplex PCR approach, as discussed below (Table 1). However, no review papers have been published including recommendations and the routine diagnostic implications of this approach. To update existing knowledge about the direct diagnosis of CAM by metagenomics, we conducted a literature search for studies applying mNGS directly to CSF for the diagnosis of CAM.

TABLE 1

ReferencesCountryCategorySample typeTotal patientSample preparationDNA/RNA extractionMicrobial genome enrichmentLibrary preparationInstrumentSoftwareDatabase
()California, United StatesCase reportFresh CSF1NoEZ1 Viral kit (Qiagen)Turbo DNase (Ambion)Nextera XT protocol (Illumina)Illumina MiSeqSURPI pipelineNCBI GeneBank database
()Tianjin, ChinaProspective studyFrozen CSF4NoTIANamp Micro DNA Kit (TIANGEN BIOTECH)Sigma-Aldrich WGA4 Kit (WGA)Not availableBGISEQ-100 platformBurrows-Wheeler Alignment, SoapCoverage softwareMicrobial Genome Databases
()Beijing, Chinaretrospective studyFrozen CSF3NoTIANamp Micro DNA Kit (Tiangen Biotech)NoNot availableBGISEQ-100Burrows-Wheeler AlignmentMicrobial Genome Database
()MexicoCase reportFrozen CSF1NoMagNA Pure LC 2.0 instrument, Total Nucleic Acid isolation kit (Roche)TransPlex Whole Transcriptome Amplification kit WTA, (Sigma-Aldrich) and GenomiPhi V2 (Healthcare Life Sciences)Roche 454 GS FLX single-end library454 GS FLX Titanium system (Roche)GS de novo Assembler version 2.6,NCBI GenBank
()Nagoya, JapanProspective studyFresh CSF180.45-μm filter (Merck-Millipore, Temecula, CA)QIAamp Viral RNA Mini kit (Qiagen)Turbo DNase (Ambion, Darmstadt, Germany)Nextera XT DNA Sample preparation kit and ScriptSeq v2 (Illumina)Illumina MiSeq, Illumina HiSeq 2500MEGAN5, CLC workbenchMEGABLAST
()California, United StatesCase reportFresh CSF1Not availableNot availableNot availableNot availableIllumina MiseqSURPI+ computational pipelineMicrobial genome database
()Boston, United StatesCase reportFresh CSF1centrifugation 90 min/18,000 xg/4°CQIAamp Viral Mini Kit (Qiagen)TURBO DNase (Thermo Fisher)Nextera XTIllumina MiSeqKraken, de novo assemblypublished computational pipeline viral-NGS
()Nanjing, ChinaCase reportFresh CSF1NoTIANamp Micro DNA Kit (TIANGEN BIO- TECH)Sonication (Bioruptor Pico protocols)end-repaired adaptation and PCR amplification (BGI, Tianjin, China)BGISEQ-50 platformBurrows-Wheeler AlignmentMicrobial genome database
()Boston, United StatesCase reportFresh CSF1TURBO DNase (Thermo Fisher)QIAamp Viral Mini Kit (Qiagen)TURBO DNase (Thermo Fisher)Nextera XT (Illumina)Illumina MiSeq, HiSeq 2500Kraken, Geneious version 8.1.7NCBI GenBank Database
()Beijing, ChinaProspective studyFrozen CSF12Not availableNot availableNot availableNot availableBGISEQ-500/50 platformBurrows-Wheeler AlignmentMicrobial genome Database
()Zurich, SwitzerlandCase reportFresh CSF1centrifugation and filtrationNot availableDNase treatmentNextera XT (Illumina)MiSeqVirMet pipelineNCBI GenBank database
()BangladeshRetrospective studyFrozen CSF91Not availableNot availableNot availableNextera XT (Illumina)Illumina NovaSeqIDseq bioinformatics pipelineNCBI GenBank database
()Beijing, ChinaRetrospective studyFrozen CSF23glass beads, vortexed 20 min, centrifuged at 8000 rcfTIANamp Micro DNA Kit (TIANGEN BIOTECH)Noend-repaired adaptation and PCR amplification (BGI, Tianjin, China)BGISEQ-100Mapping with WBA, BLASTMicrobial genome database
()California, United StatesRetrospective studyFresh CSF204Not availableNot availableNot availableNextera XT (Illumina)Illumina HiSeqSURPI+ pipelineNCBI GenBank database
()Hebei, ChinaCase reportFresh CSF1NoTIANamp Micro DNA Kit (Tiangen Biotech)Noend-repaired adaptation and PCR amplification (BGI, Tianjin, China)BGISEQ-100Burrows-Wheeler AlignmentMicrobial genome database
()Amsterdam, NetherlandsRetrospective studyFrozen CSF45Centrifugation TURBO DNase (Thermo Fisher)Manually extracted Boom methodMseI (T?TAA; New England Biolabs)VIDISCA library preparationIon PGM SystemTaxonomer, CodonCode Aligner (version 6.0.2)UBLAST
()Beijing, ChinaRetrospective studyFresh CSF135NoTIANamp Micro DNA Kit (DP316, Tiangen Biotech, Beijing, China).NoBGISEQ-500 standard protocolBGISEQ-500 sequencingBurrows-Wheeler AlignmentMicrobial genome database
()California, United StatesRetrospective studyFresh CSF95FastPrep-24 bead beater (MP Biomedicals)EZ1 Virus Mini Kit v2.0 (Qiagen)NEB Microbiome Enrichment Kit (New England Biolabs) Turbo DNAse (Thermo-fisher)Nextera XT DNA Library Prep Kit (Illumina)Illumina HiSeqSURPI+ pipelineGenBank reference database
()Agogo, GhanaRetrospective studyFrozen CSF70NoMagMAX Viral RNA Isolation Kit (Life Technologies)NoBGISEQ-500 standard protocolIllumina MiSeqCLC workbench, Trinity v2.6.6, Geneious v11, DIAMOND v0.9.6NCBI GenBank database
()Yangzhou, ChinaCase reportFresh CSF4CentrifugationTIANamp Micro DNA Kit (TianGen Biotech)Ultrasonicator (Covaris)VAHTS Universal DNA Library Prep Kit for Illumina V3 kitIllumina NextSeq500Burrows-Wheeler AlignmentMicrobial genome database
()Hunan, ChinaCase reportFresh CSF1NoTIANGEN DNA Mini kit DP316 (Tiangen Biotech, Beijing, China)NoNot availableIllumina NextSeqBurrows-Wheeler AlignmentMicrobial genome database
()Hunan, ChinaCase reportFresh CSF1Not availableNot availableNot availableNot availableNot availableNot availableNot available
()ChinaProspective studyFrozen CSF213Glass beads, vortexNot availableNot availableNot availableBGISEQ-500Burrows-Wheeler AlignmentMicrobial genome database
()Shanghai, ChinaProspective studyFrozen CSF51Glass beads, vortex 2800-3200RPM for 30 minTIANamp Micro DNA Kit (TIANGEN BIOTECH)Noend-repaired adaptation and PCR amplification (BGI)BGISEQ-50 platformBurrows–Wheeler AlignmenMicrobial Genome Databases
()Wenzhou, ChinaCase reportFresh CSF1Not availableNot availableNot availableNot availableBGISEQ platformBurrows-Wheeler AlignmentMicrobial Genome Databases
()Shanghai, ChinaCase reportFresh CSF1Not availableNot availableNot availableNot availableBGISEQ platformBurrows-Wheeler AlignmentMicrobial Genome Databases
()London, United KingdomProspective studyFresh CSF12Filtration and Turbo DNAse treatmentPureLink Viral RNA/DNA Mini Kit (Invitrogen)NoNextera XT DNA library prep kit (Illumina)Illumina MiSeqTrimmomatic v0.39, PRINSEQ, mapping with PALADIN, BWA MEMIn-house database comprising the RefSeq viral protein sequences from NCBI
()Leiden, NetherlandsProspective studyFrozen CSF41NoMagNApure 96 DNA and Viral NA Small volume extraction kit (ROCHE)SpeedVac vacuum con- centrator (Eppendorf), SeqCap EZ Hypercap probes (Roche)NEBNext Ultra II Directional RNA Library prep kit (New England Biolabs)Illumina NovaSeq6000Illumina data analysis pipeline RTA3.4.4 and bcl2fastq v2.20, Genome Detective version 1.111An index database constructed from NCBI
()Barcelona, SpainRetrospective studyFrozen CSF20NoDirect-zol RNA MicroPrep with TRI reagent (Zymo Research)Depletion of Abundant Sequences by Hybridization (DASH)NEBNext Ultra II Directional RNA Library prep kit (New England Biolabs)Illumina HiSeq 4000 instrumentGeneious version 10.2.3, SPAdes version 3.10.0, MUSCLE, MAFFT.Local database
()Boston, United StatesCase reportFrozen CSF1Not availableNot availableNot availableNot availableIllumina HiSeq 2500SURPI+ pipelineNCBI GenBank database
()Sydney, AustraliaProspective studyFrozen CSF18NoRNeasy plus universal kit (QIAGEN)NoTrio RNA-Seq kit (NuGEN Technologies, United States) wasIllumina NovaSeq platformBlastn, Blastx, Diamond, MegahitNCBI GenBank databases,
()Hangzhou, ChinaCase reportFresh CSF1Not availableNot availableNot availableNot availableBGISEQ-500 sequencingNot availableNot available
()Hunan, ChinaCase reportFresh CSF1NoNot availableNoNexter XTNextSeq 550KrakenIn-house database
()Guangzhou, ChinaCase reportFrozen CSF1Not availableTIANamp Magnetic DNA Kit (Tiangen)Not availablePACEseq mNGS (Hugobiotech)NextSeq 550Burrows-Wheeler AlignmentMicrobial genome database
()Hunan, ChinaCase reportFresh CSF1Not availableNot availableNot availableNot availableNot availableNot availableNot available
()Guangzhou, ChinaCase reportFresh CSF1centrifugation 5 min at 15,000 rpmmagnetic beads [Sagene, Guangzhou, CHINA]NoNexter XTIllumina NextSeq 550 DXNot availableNot available
()Hebei, ChinaRetrospective studyFresh CSF7Not availableNot availableNot availableNot availableBGISEQ-500 sequencingBurrows-Wheeler AlignmentMicrobial genome database
()Ohio, United StatesProspective studyFrozen CSF37NoQIAamp Viral RNA Mini Kit (Qiagen)NoTruSeq Universal kit (Illumina)Illumina HiSeq4000FastQC, Cutadpat and PRINSEQ tools, Bowtie2 mapper 2.0.6, CDHIT tool. de novo assembled using MIRA (v 4.0), MegaBLASTNCBI GeneBank database
()ChinaCase reportFrozen CSF1Not availableNot availableNot availableBGISEQ-500 standard protocolBGISEQ 50 MGI DNBSEQBurrows-Wheeler AlignmentMicrobial genome database
()Jiangsu, ChinaRetrospective studyFrozen CSF1NoTIANamp Magnetic DNA Kit (Tiangen)NoKAPA Hyper Prep Kit (KAPA Biosystems) accordingIllumina NextSeq 550DxTrimmomatic v.0.36 software, Bowtie2 software. Kraken 2 softwareMicrobial genome database
()Changsha, ChinaCase reportFresh CSF1Not availableNot availableNot availablePACEseq mNGS test (Hugobiotech)Illumina NextSeq 550Not availableNot available
()Riyadh, Saudi ArabiaCase reportFrozen CSF1NoDNeasy Blood and Tissue Kits (QIAGEN)NoNuGEN Ovation Ultralow Library System V2 (NuGEN)Illumina HiSeq 4000, Illumina iSeq 100MEGAHIT assembler v1⋅1 ⋅4, BBmap with 0 ⋅98, Metabat v2 ⋅12 ⋅1, SpadesNCBI GenBank database
()Zhejiang, ChinaCase reportFresh CSF1Not availableNot availableNot availableNexter XTIllumina NextSeqKrakenKraken microbial database
()Boston, United StatesProspective studyFresh CSF68NoQIAamp viral RNA minikit (Qiagen)NEBNext microbiome DNA enrichment kit (New England BioLabs)Nextera XT DNA library prep kit (Illumina)Illumina MiSeqKrakenUniq, BLASTNCBI GenBank database
()Marseille, FranceCase reportFresh CSF1Proteinase K 20 minQIAamp Viral RNA Mini Kit solutions (Qiagen)Turbo DNase (Thermo Fisher) andNextera XT V2Illumina iSeq 100Spade, BLAST, CLC workbenchNCBI GenBank database
()Guangzhou, ChinaRetrospective studyFrozen CSF11Not availableNot availableNot availableNot availableBGISEQ platformBurrows-Wheeler AlignmentMicrobial Genome Databases
()Marseille, FranceCase reportFresh CSF1Proteinase K 20 minVirus Mini Kit v2.0 (Qiagen)Spiked primer enrichmentNextera XT V2Illumina Miseq, iSeq 100Spade, BLAST, CLC workbenchNCBI GenBank database
()Marseille, FranceCase reportFresh CSF1Proteinase K 20 minEZ1 DNA Kit (Qiagen)NoOxford Nanopore MinION library preparationOxford Nanopore MinIONEPI2ME, Kraken-2, PavianNCBI GenBank database
()Marseille, FranceCase reportFresh CSF1Proteinase K 20 minEZ1 DNA Kit (Qiagen)NoOxford Nanopore MinION library preparationOxford nanopore MinION, Illumina iSeqEPI2M2, Spades, CLC genomic workbenchNCBI GenBank database
()Beijing, ChinaProspective studyFresh CSF38centrifugation 10 min at 13,000 rpmQIAamp DNA Microbiome Kit (Qiagen)NEBNext microbiome DNA enrichment kit (New England BioLabs)Nextera XT kit v2 Ion Torrent end-repair libraryIllumina MiSeq, Ion Torrent ProtonBurrows-Wheeler alignment wasMicrobial genome databases
()Marseille, FranceCase reportFresh CSF1Proteinase K 20 minEZ1 DNA Kit (Qiagen)NoOxford Nanopore MinION library preparationOxford Nanopore MinIONEPI2ME and CLC Genomics Workbench, softwareNCBI GenBank database

Metagenomics pipelines.

Methods

Literature Search

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (). A systematic bibliography search was conducted on PubMed, Google Scholar, Web of Science, Microsoft Academic, Crossref and Semantic Scholar databases for studies published in English between January 1, 2015 and December 31, 2021 and related to the diagnosis of CAM by metagenomic NGS. Duplicate studies were removed in a first screening and the remaining papers were further screened based on title and abstract, according to the eligibility criteria. After full-text screening, only studies that met the inclusion criteria were included in this review, using the keywords: “metagenomic,” “diagnosis,” “meningitis,” “encephalitis,” “next generation sequencing,” and “cerebrospinal fluid.” These keywords were used in combination to perform an exhaustive search, as presented in Figure 1.

FIGURE 1

Eligibility and Data

Studies with the following criteria were included in this review: Studies using mNGS-CSF for: (1) case reports; (2) prospective series; (3) retrospective series for non-routinely detected pathogens” (Table 1 and Supplementary Data). Review articles, studies performed on animals, non-clinical studies, and benchmarking studies were not included. Data extracted from selected studies included: first author name and year of publication, authors’ country, nucleic acid extraction method including commercially available kits, mNGS platform and sequencer instrument, pipeline data analysis and software, and reference database used for pathogen genome detection of identified microorganisms. Included were the total number and discordance/agreement of mNGS data with data yielded by routinely used methods, including molecular tests and culture. These data were reviewed and extracted after validation of the inclusion criteria by the authors.

Results

Included Studies

Bibliographic searches identified 3,341 articles and, following the Prisma diagram (Figure 1), 2,080 articles were removed after deduplication and 1,199 additional articles were removed by title and abstract screening. From the 62 remaining articles, 11 articles were removed after full-text reading, including four review articles and seven non-relevant articles, resulting in 51 articles analysed in this review.

Study Characteristics

Participants

In 2015, the first reported application of mNGS directly on CSF (and brain biopsy) enabled the post-mortem diagnosis of Astrovirus-related encephalitis in an immunocompromised patient (). A 7-year review of publications indicated only nine studies published between 2015 and 2018, ten in 2019 and 42/51 (82%) publications between 2019 and 2021, including 22 (43%) publications in 2021 (Figure 2). As for the geographic origin of published studies, 28 (56%) were published in Asia, including 25 (49%) from Chinese laboratories (Table 1), one each from Saudi Arabia (), Bangladesh (), and Japan () (6.1%); nine in the United States (Table 1); one in Mexico (); five in France (10%) (Tabel 1); two in Netherlands (; ); and one each in Switzerland, the United Kingdom, and Spain (; ; ). One study was also published in Guinea and another in Australia (; ; Figure 2).

FIGURE 2

Workflow

Nucleic Acid Procedures

Only CSF investigations [apart from one post-mortem brain biopsy in the founding study ()] were reviewed in this study. Depending on the prospective or retrospective nature of the investigations, fresh CSF was used in 63% of studies and frozen CFS in 37% of studies. DNA and RNA were manually extracted in 44% of studies, automatic extraction was performed in 20%, and 36% of studies did not report on the nucleic acid extraction method. The sample pre-treatment reported in 18/51 (35%) studies included centrifugation (∼15,000 g), filtration and vortexing in 12 studies, DNase treatment in four studies (; ; ; ) and proteinase K treatment in five studies (Table 1; ; ; ; ; ,; ), while no pre-treatment was performed in 15 studies and no such information was provided in 16 studies (Table 1). Extracted nucleic acids (retro-transcribed RNA and DNA) were always quantified using either a Qubit fluorometer and a Qubit DNA and RNA High Sensitivity Assay Kit (Life Technology, United States) (Table 1; ; ; ; ; ,; ), or NanoDrop spectrophotometer (Thermo Fisher Scientific, United States) (). Optimisation in the human-to-microbial ratio of DNA was achieved by intermediate microbial genome enrichment or human genome depletion (Table 1). DNase treatment was used to reduce human DNA in extracted RNA for mNGS investigations of RNA-viruses (Table 1; ; ; ; ; ,; ), and bead-based capture kits were also used to remove human DNA (; ; ; ). Further, microbial genomes could be enriched by specific primer amplification for whole genome investigations (Table 1). cDNA and double-stranded synthesis were needed prior to library preparation when RNA was investigated (Table 1), and in the case of RNA genome enrichment, an RT-one-step protocol was followed by reverse-transcription and pathogen genome amplification (). In two studies, DNA was mechanically broken prior to library construction (; ).

Next Generation Sequencing Library Preparation and Sequencing

Three main protocols were used for mNGS library preparation (Table 1 and Figure 3). Illumina pair-end protocols and reagents were used for mNGS library preparation in 19/51 (37%) studies, including Nextera XT DNA Library Prep Kit in 16/51 (31%) and one each with the TruSeq Universal kit () and VAHTS Universal DNA Library Prep Kit (). Standard BGISEQ pair-end protocols were used in 6/51 studies. Two studies used the PACEseq mNGS test (Hugobiotech, Beijing, China) (; ), two studies used VIDISCA and Ion Torrent end-repair library (; ), and one study each used the NEBNext Ultra II Directional RNA Library prep kit (New England Biolabs, Ipswich, MA, United States) (; ), the KAPA Hyper Prep Kit (Kapa Biosystem, Potters Bar, United Kingdom) (), the NuGEN Ovation Ultralow Library System V2 kit (NuGEN Technologies, United States) () the Trio RNA-Seq kit (NuGEN Technologies) (), and the Roche 454 GS FLX single-end library (Roche Diagnostics, Branford, CT, United States) (). In three studies, the mNGS library was constructed following the single-end Oxford Nanopore library preparation protocol (,, ). Finally, the library preparation protocol and kits were not reported in 14 studies (Table 1 and Figure 3). mNGS libraries were sequenced using Illumina sequencers in 30/51 (59%) studies, MiSeq platform in 11/30, HiSeq platform in 8/30, Nextseq platform in 6/30, iSeq 100 platform in 4/30, and 3/30 studies used the NovaSeq platform. BGISEQ platforms were used in 12/51 (24%) of studies (Table 1), including BGISEQ-50, 100, and 500 platforms, while three studies used the Roche 454 GS FLX Titanium system platform, Ion PGM System platforms and Ion Torrent Proton Sequencer (Life Technologies, United States), respectively (; ; ). Real-time sequencing with the Oxford Nanopore MinION sequencer was used in three studies (,, ) and no information about the sequencer was reported in five studies (Table 1). The use of Nanopore technologies, i.e., single-long-read sequencing platforms combined with direct read blasting against the NCBI GenBank database using EPI2ME online software1 or against an internal database using in-house pipelines, allowed for pathogen identification within the first minutes of sequencing (). Furthermore, all additional pieces of information such as bacteria profiling and genotyping, was obtained in less than 6 h (,, ).

FIGURE 3

Sequence Data Analysis

Next generation sequencing data quality was controlled using FastQC (; ), and the human genome could be removed by mNGS reads mapping to the Homo sapiens reference genome (hg19) using Burrows-Wheeler Alignment (BWA) in 40% of studies. Non-mapped reads could be assembled using Spades and de novo assembly or directly against the reference genome using the BWA and CLC Genomic workbench (Table 1). For an exhaustive pathogen genome investigation, mNGS data were blasted [BLAST: Basic Local Alignment Search Tool (nih.gov)] against the NCBI GenBank database or against an in-house microbial genome database, regardless of the sequencing technology, yet with different timing as for Illumina and Nanopore technologies, as mentioned above (Table 1). The sequence-based ultra-rapid pathogen identification computational pipeline (SURPI) was a powerful method for pathogen identification, combining blast and mapping of both pathogen genome and protein encoding sequences directly from mNGS outputs (; ). When only one specific aetiology was investigated, a reference database constructed with such specific pathogen genomes and proteins could be used for its accurate identification (; ). Depending on the previous pathogen identification, a specific pathogen genome was extracted directly as consensus sequences in FASTA files, after mapping to the reference genome directly from CLC and BWA software for further analysis (Table 1 and Figure 3). Virus genotyping based on hit-blast identified strains could be confirmed by phylogenetic analysis based on sequence similarity level, while bacteria genotyping could be predicted online by Multi-Locus Sequence Typing online platform (Figure 3). Also, the in silico antibiotic resistance pattern could be predicted by aligning bacterial genome sequences against online databases of antibiotic-resistance encoding genes (Table 1; ; ; ; ; ,; ), mostly represented by ResFinder on the Centre for Genomic Epidemiology server (; ,, ).

Pathogen Detection and Characterisation

Of the 51 studies analysed, a total of 1,248 CSF samples collected from CAM patients were investigated in parallel by mNGS reference and routine molecular diagnosis and culture. Routine methods and mNGS yielded concordant results in 1,031 (82.6%) CSF samples, including no pathogen documentation in 566 CSF samples and concordant identification in 465 CSF samples. Discordant results were observed in 217 (17.4%) CSF samples, including 87 CSF samples documented by routine methods only, 103 CSF samples documented by mNGS only, and 27 CSF samples in which documented microorganisms differed from routine methods and mNGS. Altogether, the 116 detected microorganisms included 63 bacteria, 38 viruses, 10 fungi, and five parasites. mNGS detected 106/116 (91.4%) different microorganisms, including 50 (43.1%) detected by mNGS only, whereas 56 microorganisms were detected by both routine methods and mNGS. In addition, five microorganisms were detected by routine molecular diagnosis only, four microorganisms by culture only and one Enterococcus gallinarum strain was diagnosed by routine molecular diagnosis and culture (Figure 4). Further, there was concordant documentation of 56 different pathogens, including 30 bacterial pathogens, 19 viral pathogens, six fungi and one Balamuthia mandrillaris (B. mandrillaris) as the only amoeba detected in a CSF sample (Table 1 and Figure 4). Of the 217 CSF samples in which mNGS investigation yielded results discordant with the routine method, mNGS conclusively found a pathogen in 38/103 CSF samples in which routine investigations found no pathogen, as reported in 25/51 studies: mNGS over-detected RNA viruses, including Human rhinovirus and Human coronavirus (), Coxsackievirus 9 and Mumps virus (), Saint-Louis Encephalitis virus (), Powassan Virus (), Toscana virus (), Jamestown Canyon virus (), Enterovirus A71 (), and Hepatitis E virus (), while only HSV-1, HHV-6, and EBV were identified as DNA viruses (; ). Bacterial pathogens documented in 11% of these cases included Listeria monocytogenes in four cases (; ), Ureaplasma parvum in three cases (; ; ) and one case each was detected of Klebsiella pneumoniae (), Pasteurella multocida (), Enterococcus faecalis (), Nocardia farcinica (), Streptococcus suis (), and Psychrobacter sp. (). Toxoplasma gondii, B. mandrillaris, and Naegleria fowleri parasite species were identified in four patients (N. fowleri in two patients) in whom routine diagnostic methods completely missed N. fowleri (; ; ; ), while Coccidioides posadasii was the single fungal infection exclusively detected by mNGS in one patient with no previously documented infectious meningitis (; Supplementary Data; Figure 4).

FIGURE 4

Limitations

A review of published data indicated that in 4/217 cases, mNGS failed to detect a pathogen when the pathogen had been detected by real-time polymerase chain reaction (RT-PCR) with a Ct > 37, mainly due to a low pathogen inoculum (), as well as for a pathogen detected by immunodetection assay (). These limitations could be due to:

  • 1)

    Storage conditions: storage of the CSF at temperature above -80°C may cause nucleic acid molecule damage. Moreover, lack of proper storage in the presence of RNase inhibitors, will likely result in RNA viruses undergoing some degradation.

  • 2)

    Limited CSF volume affecting the DNA quantity used for NGS library preparation (), especially for the Oxford Nanopore libraries, which require 1 μg of DNA (,).

  • 3)

    A CSF leukocyte count (>103/mL) increasing the ratio of human genome, which required microbial genome enrichment (; ; ; ; ,; ), and human genome depletion (Table 1). DNase treatment usually used to reduce human DNA in the extracted CSF can, therefore, generate false negative results, due to the degradation of the DNA pathogens (). Alternatively, one limitation is related to the elimination of human DNA prior tosequencing, such as CSF pathogens whose genome is partially or totally integrated into the human genome, such as the case of HHV-6 (). Library preparation and cross-contamination removal during sample preparation is essential to avoid any confusion of detection and interpretation, especially when working on several samples in the same run (Table 1; ; ; ; ; ,; ). Depth, coverage, and sequence quality may be influenced by the sequencing platforms, as well as the kit used for library preparation, which is relative to the initial pathogen load in the CSF (Table 1; ; ; ; ; ,; ), depending on the number of sequencing cycles for paired-end sequencing and the read size for single-end long read sequencing. Assembly and data analysis mainly depend on the quantity and quality of reads generated by sequencers (,,). Pathogen identification is mainly based on in-house databases constructed with a limited number of pathogen genomes and species downloaded from the NCBI GenBank (Table 1) used for blast and mapping, which needs regular updating for the exhaustive identification of all possible microbial genomes detected in the CSF sample (Table 1). Performance analysis requires powerful software and pipelines to blast all mNGS data against the GenBank database, which is limited by cost and accessibility, such as the EPI2ME software used for real-time analysis of sequencing data generated by Nanopore Platforms (,, ).

Discussion

Direct mNGS appears to be a relevant alternative diagnostic approach to simplex and multiplex RT-PCRs for the POC diagnosis of CAM. mNGS adds one-shot pieces of medically relevant information, including genotyping and antimicrobial susceptibility profile, in comparison to current PCR-based methods (,; ). The suitability of this new approach should be evaluated in all laboratories already providing molecular detection of pathogen-genome sequences in the CSF of patients with meningitis, and as a new technique in new POC laboratories bypassing previous multiplex RT-PCR (; ; ). The basis for such an evaluation includes the flow of samples and cost of mNGS relative to multiplex PCR. Indeed, mNGS also provides an antimicrobial susceptibility profile to guide medical management of the patient (,, ) and genotyping to detect outbreaks and to guide source tracing compared to multiplex PCRs (). Such genotyping information may be medically relevant and associated with a particular prognosis of CAM (case of a few Enteroviruses) and certainly relevant to source tracing in the context of clustered cases and outbreaks. Compared to the limited number of the pathogens investigated by routine multiplex RT-PCR, mNGS identified 106 different microorganisms in CSFs from patients with meningitis, i.e., covering 91.4% of total microorganisms identified here. This allowed the detection of pathogen genomes in 38 non-routinely documented CSFs. In addition, mNGS can operate within infinitely greater open databases than those currently supporting available multiplex RT-PCR assays, which rely on fewer than 30 such entries, whereas genome sequence databases such as NCBI consist of more than 83,124 complete microbial genomes (including bacteria, viruses, fungi, and parasites), offering opportunities for the diagnosis of rare pathogens, as reviewed in this study.

Finally, a few current limitations of the mNGS approach are opportunities for improvements from the perspective of routine use. Most enzymes used in the above-described sequencing protocols were issued from cloning in competent bacteria such as Escherichia coli (E. coli) (), meaning potential contamination by E. coli DNA and a risk of a false-positive diagnosis of E. coli meningitis. As an illustration, Nanopore sequencing results regularly consisted of E. coli DNA resulting from the recommended internal library control, and Shigella and T4 phage reads issued from repair and ligation enzymes (,, ). This limit could be overcome by replacing the E. coli control and using the human genome as an internal control, in line with our own practice. The quantity of data generated by sequencing was sometimes insufficient to support an accurate interpretation, requiring additional enrichment and human genome depletion steps to improve the sensitivity and specificity of detection of CAM causative agents (; ; ; ; ). Moreover, sequence variation linked to high mutational levels, as observed in RNA viruses including Enterovirus (; ,), with more than 300 genotypes (), and obscuring the identification capability of the mNGS approach, further indicates the necessity for pathogen genome enrichment to achieve appropriate sequencing depth. This is usually limited by the CSF volume which makes it not possible to extract the DNA and RNA separately (). The sensitivity of mNGS depended on the nature of the causative pathogen, being lower than routine techniques for bacterial and fungal meningitis, at 73.3% and <85%, respectively (; ). In contrast, mNGS appeared to be highly sensitive (>90%) in cases of mycobacterial and viral meningitis (; ; ; ). However, human genome depletion by DNase treatment can produce false-negative results in the case of RNA investigation, by degrading the pathogen DNA (; ).

The mNGS approach is not currently standardised and remains in its infancy. Microbiologists may, therefore, wish to develop different strategies to investigate RNA and/or DNA pathogens, relying on available mNGS materials and reagents as well as mNGS platform, and in-house pipelines using local epidemiology-driven, specific pathogen genome databases (Figure 3). Finally, because this identification is database-dependent, attention should be given to curating and updating local databases (; ; ). In contrast to routine tests based on nested and semi-nested PCRs generating up to 25% false-positive results (), the mNGS approach does not involve any prior amplification and no specific pathogen target, thus limiting the opportunity for such false-positives. Additional information about genotyping and in silico antibiotic susceptibility testing was added, even in cases of uncultured bacteria.

As a time and cost-effective approach, real-time mNGS could be implemented in POC laboratories for the diagnosis of CAM, especially with regards to undocumented meningeal disease ().

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Statements

Author contributions

MM: literature search, data collection, data cleaning, data interpretation, validation, and writing of the manuscript. JL and MD: design of the study, data interpretation, validation, funding, critical review of the manuscript, coordination, and direction of the work. The data presented here were extracted by MM and validated by JL and MD after review. All authors have read and approved the manuscript.

Funding

MM was a Ph.D. student supported by the Fondation Méditerranée Infection. This work was supported by the French Government under the Investissements d’Avenir (Investments in the Future) programme managed by the ANR [Agence Nationale de la Recherche (National Agency for Research)] (reference: Méditerranée Infection 10-IAHU-03).

Acknowledgments

We thank the support provided by the Fondation Méditerranée Infection, IHU Méditerranée Infection, Marseille, France. MM received a Ph.D. grant from the Fondation Méditerranée Infection.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2022.926240/full#supplementary-material

References

Summary

Keywords

metagenomic next generation sequencing, diagnosis, point-of-care laboratory, multiplex RT-PCR, culture, pathogen genome, antibiotic resistance, genotyping

Citation

Morsli M, Lavigne JP and Drancourt M (2022) Direct Metagenomic Diagnosis of Community-Acquired Meningitis: State of the Art. Front. Microbiol. 13:926240. doi: 10.3389/fmicb.2022.926240

Received

22 April 2022

Accepted

06 June 2022

Published

05 July 2022

Volume

13 - 2022

Edited by

Tianmu Chen, Xiamen University, China

Reviewed by

Peter Michael Keller, University of Bern, Switzerland; Ana Valero-Rello, University of Valencia, Spain

Updates

Copyright

*Correspondence: Michel Drancourt,

This article was submitted to Infectious Agents and Disease, a section of the journal Frontiers in Microbiology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics